3M has announced the sale of "substantially all" of 3M Drug Delivery Systems to Altaris Capital Partners for approximately $650 million. 3M will keep a 17% interest in the new business, which is expected to employ approximately 900 of the current employees after the sale is completed. 3M's inhalation products include standard MDIs, a nasal MDI, and the Intelligent … [Read more...] about 3M Drug Delivery Systems sold to Altaris Capital Partners
Business
Windtree Therapeutics announces completion of $26.4 million private placement
Aerosurf inhaled surfactant developer Windtree Therapeutics has announced the completion of a $26.4 million private placement of common stock and warrants. Net proceeds were approximately $23 million. Windtree is developing several inhaled drugs delivered via the company's proprietary Aerosol Delivery System (ADS). In addition to Aerosurf inhaled KL4 surfactant, … [Read more...] about Windtree Therapeutics announces completion of $26.4 million private placement
Chiesi announces plans for lower carbon footprint HFA 152a inhaler by the end of 2025
Chiesi announced that the company has signed an agreement with Koura (formerly Mexichem) for supply of HFA 152a propellant as part of a €350 million plan to bring a pMDI with a 90% lower carbon footprint to market by the end of 2025. The company, which has also pledged that it would be carbon neutral by 2035, made the announcement at the Nations Climate Change … [Read more...] about Chiesi announces plans for lower carbon footprint HFA 152a inhaler by the end of 2025
UCB announces US launch of Nayzilam midazolam nasal spray
According to UCB, Nayzilam midazolam nasal spray will be available in the US as of December 2, 2019. UCB acquired the nasal spray from Proximagen in April 2018, and the FDA approved Nayzilam for the treatment of seizure clusters in epilepsy patients 12 years old and older in May 2019. The company said that Nayzilam is expected to cost $40 for a box containing two … [Read more...] about UCB announces US launch of Nayzilam midazolam nasal spray
Lupin launches Adhero inhaler monitoring device in India
Lupin has launched its new Adhero connected inhaler monitoring device in India, the company said. According to Lupin, the company collaborated with Aptar Pharma on the device, which attaches to the tops of MDIs. The Adhero sensors allow for monitoring of inhaler use, and data are uploaded to a "MyAdhero" app via Bluetooth. The usage data are also accessible to … [Read more...] about Lupin launches Adhero inhaler monitoring device in India
Iconovo gets Japanese patent for ICOres DPI
DPI developer Iconovo has announced that the Japanese Patent Office has granted the company a patent covering its ICOres dry powder inhaler. According to Iconovo, Sweden and European patents related to ICOres have already been issued. In March 2019, Iconovo announced that CBC Corporation was taking over development responsibilities from Amneal Pharmaceuticals for … [Read more...] about Iconovo gets Japanese patent for ICOres DPI
Iconovo and Crystec sign collaboration agreement for DPI development
Device maker Iconovo and particle engineering specialist CrystecPharma have announced a non-exclusive collaboration agreement for development of dry powder inhalers. The companies say that they plan to develop engineered particles using CrystecPharma's modified supercritical anti-solvent (mSAS) technology for delivery via one of Iconovo's devices. According to the … [Read more...] about Iconovo and Crystec sign collaboration agreement for DPI development
Kind Consumer launches Voke nicotine inhaler in the UK
Kind Consumer has announced the UK launch of its breath activated Voke 0.45mg nicotine inhaler, which will be available to consumers by direct online purchase at a price of £11.99. The Voke inhaler was approved by the MHRA for general sale for the relief or prevention of nicotine cravings and withdrawal symptoms in September 2014. In January 2017, British American … [Read more...] about Kind Consumer launches Voke nicotine inhaler in the UK
MannKind gets 2nd development milestone payment for dry powder treprostinil
MannKind Corporation said that it has reached the second milestone in its development of Treprostinil Technosphere (“TreT”), a dry powder formulation of treprostinil for inhalation that the company is developing for the treatment of pulmonary arterial hypertension in partnership with United Therapeutics. In April 2019, MannKind announced that United Therapeutics had … [Read more...] about MannKind gets 2nd development milestone payment for dry powder treprostinil
Insmed appoints Martina Flammer as Chief Medical Officer, provides update on Arikayce
Insmed has announced the appointment of Martina Flammer as Chief Medical Officer, effective mid-December 2019. Flammer was most recently Senior VP Customer Value at Boehringer Ingelheim and her previous positions include VP Medicine, Regulatory Affairs & Pharmacovigilance at BI Canada; VP Clinical Development & Medical Affairs of BI's Specialty Care Business … [Read more...] about Insmed appoints Martina Flammer as Chief Medical Officer, provides update on Arikayce